GA-VENTIV-TECHNOLOGY
21.7.2022 11:02:06 CEST | Business Wire | Press release
Ventiv Technology, the leading provider of risk, insurance and underwriting solutions, announced today its inclusion in the Management des Risques et des Assurances de l’Entreprise’s (AMRAE) 2022 Panorama report as leaders in Analytics and Insurance. The association’s 14th annual market analysis is based on vendor and risk manager questionnaires. Among the 55 vendors evaluated, Ventiv was one of only four to be recognized as a leader in the artificial intelligence quadrant, having both functional and technical coverage. Ventiv was one of five vendors to have that same distinction in the insurance quadrant.
According to the report, 63% of risk managers look for one tool to meet all their functional needs, audit, risk management, insurance, internal control, etc., highlighting the growing industry trend towards converging risk management systems that are cross-functional.
“Ventiv continues to grow and expand its offerings to stay on the forefront of tech and innovation,” said Steve Cloutman, Managing Director of Ventiv. “This year's report reinforces known trends and where we are headed as an industry. We look forward to continuing to be a part of moving the industry forward.”
The report also found that ease of use and reporting capabilities are the top two criteria risk managers seek when evaluating a RMIS platform. In addition, the report listed AI as one of the top three functionalities that are on the agenda for future development for most firms.
Ventiv is a differentiator when it comes to its AI-powered data analytics software. Its AI and machine learning algorithms help clients predict outcomes, prioritize time and resources, and improve operational efficiency. Combined with the company’s hands-on customer support and software offerings, clients can easily scale their risk management programs as they grow.
With more than 450 clients across Europe, North America, and Asia, Ventiv provides RMIS solutions to some of the largest global companies across a range of industries, including healthcare, manufacturing, and hospitality. This is the company’s first year being included in the report which was submitted in collaboration with EY.
The AMRAE Panorama Report is an annual publication that presents a global view of RMIS trends, market practices and details on the latest technology in the marketplace. Since 2008 AMRAE has approached the survey with a neutral point of view to provide valuable insights for risk management professionals looking for the latest info on RMIS.
Download the full report or visit Ventiv’s website for more information.
About Ventiv Technology
Ventiv Technology is a leading global provider of risk management information systems (RMIS), enterprise risk management (ERM), insurance claims, billing, policy, and administration technology integrated with its market-leading analytics and predictive models. Ventiv Technology’s SaaS and on-prem solutions are deployed by brokers, insured corporate entities, federal and regional governments, third party claims administrators (TPAs), and risk pools across a variety of industries including transportation & logistics, retail, financial services, leisure & hospitality, carriers & insurers, energy, aviation, manufacturing, government & public entities, and many more.
With over 45 years’ experience, Ventiv proudly boasts over 450 institutions as its customers and more than 350,000 users of Ventiv’s technology in over 40 countries. Ventiv’s global footprint and experienced team of industry veterans delivers insight to organizations that allows our customers to predict, manage, and respond to risk.
For more information, please visit https://www.ventivtech.com or @VentivTech .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220721005099/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Thales Builds Cryptographic Security for the Age of AI and Post-Quantum Computing14.9.2026 09:00:00 CEST | Press release
Thales launches Luna 8, a new hardware security module (HSM) to provide future-ready, quantum resistant security to protect critical data and applications Powered by a Thales designed cryptographic processor, it delivers unparalleled performance, enhanced protection and the flexibility to adapt to new security needs Drawing on decades of cryptographic expertise, Luna 8 combines trusted security with support for emerging technologies, including post quantum cryptography According to the 2026 Thales Data Threat Report, the threat of Harvest Now, Decrypt Later (HNDL) attacks was the top-cited risk, with 59% of organizations reporting that they are prototyping and evaluating post-quantum cryptography (PQC) algorithms to prepare for the quantum era. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804748922/en/ ©Thales To help organizations turn this readiness into deployment,Thales, a global leader in advanced technologies, tod
U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations14.9.2026 09:00:00 CEST | Press release
Acceptance is based on pivotal Phase 3 data demonstrating rapid, durable and consistent skin clearance, including in high-impact sites, in a convenient once-daily pill Results from nearly 3,000 patients support potential for next-generation TYK2 inhibitor to redefine oral treatment expectations in psoriasis The Prescription Drug User Fee Act (PDUFA) target action date is in the first quarter of calendar year 2027 Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) under Priority Review for zasocitinib (TAK-279) for the treatment of adults with moderate-to-severe plaque psoriasis. Zasocitinib is an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, which demonstrated rapid, durable and consistent skin clearance in Phase 3 plaque psoriasis studies.1-3 Addressing unmet needs in psoriasis treatment “Despite progress in psoriasis care, there remains a need for highly
SWISSto12 and Mitsubishi Electric Corporation Announce Strategic Partnership14.9.2026 09:00:00 CEST | Press release
The Memorandum of Understanding (MoU) and additional contract signal a new phase of collaboration on market development in the Asia Pacific (APAC) region SWISSto12 today announced a memorandum of understanding (MoU) with Mitsubishi Electric Corporation (MELCO) (TOKYO: 6503) to pursue joint opportunities on advanced payloads, radio frequency (RF) products, and market development in Japan and the APAC region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914982179/en/ Masahiko Arai, Executive Officer and Group President, Defense & Space Systems, Mitsubishi Electric, and Dr. Emile de Rijk, Chief Executive Officer, SWISSto12 Joint opportunities will leverage MELCO’s extensive satellite system expertise and integration capabilities together with SWISSto12’s proprietary 3D-printing designs and processes that form the foundation of its next-generation payloads—smaller, lighter, highly performant, yet built in materially shorter
Focused Support Launches Cavok STRIKE to Expand Link-16 Participation Across the Joint Force14.9.2026 07:00:00 CEST | Press release
Extending Link-16 interoperability without platform-level hardware integration Focused Support LLC today announced the launch of Cavok STRIKE, an integrated software capability that expands the Link-16 tactical battlespace picture by enabling additional operational platforms to participate in the Link-16 network. Modern battlefields have increasing numbers of unmanned systems, sensors, and supporting platforms operating throughout the joint battlespace. The rapid proliferation of Group 1, 2, and 3 UAS, including both expendable and recoverable systems, has created a growing need to integrate these assets into the broader tactical network. Many of these platforms provide operationally relevant information but have historically remained outside the Link-16 network due to limitations in size, weight, power, platform integration complexity, or acquisition cost. Cavok STRIKE addresses this gap by enabling platforms to participate in the Link-16 network as non-command-and-control participant
Fujirebio Expands Access to Blood-based Neurology Testing in Brazil with ANVISA Market Authorization for Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma14.9.2026 07:00:00 CEST | Press release
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that the Brazilian Health Regulatory Agency (ANVISA) has granted market authorization for the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for use on the fully automated LUMIPULSE® G immunoassay platform in Brazil. “ANVISA authorization of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays marks another important step in our mission to expand access to reliable, clinically meaningful blood-based biomarkers for clinicians and patients worldwide,” said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “By making both neurological biomarker assays available to laboratories on a single, fully automated platform, we are helping support more informed clinical decision-making across a broad range of neurological conditions and throughout the diagnostic pathway.” The Brazilian ANVISA authorizations are based on the already CE marked in vitro diagnostics (IVD) approvals of these two
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom